 Timothy Ashby
Concepts (197)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Myeloma | 37 | 2024 | 2958 | 2.730 |
Why?
| | High-Throughput Nucleotide Sequencing | 7 | 2022 | 171 | 1.200 |
Why?
| | Genomics | 10 | 2023 | 287 | 0.880 |
Why?
| | Mutation | 14 | 2022 | 1296 | 0.880 |
Why?
| | Software | 4 | 2021 | 273 | 0.870 |
Why?
| | Tumor Microenvironment | 4 | 2024 | 233 | 0.630 |
Why?
| | Clonal Evolution | 4 | 2020 | 56 | 0.590 |
Why?
| | Plasma Cells | 6 | 2023 | 223 | 0.580 |
Why?
| | Computational Biology | 4 | 2020 | 216 | 0.560 |
Why?
| | Algorithms | 4 | 2020 | 618 | 0.510 |
Why?
| | Neoplasm Recurrence, Local | 5 | 2024 | 633 | 0.480 |
Why?
| | Monoclonal Gammopathy of Undetermined Significance | 3 | 2024 | 115 | 0.460 |
Why?
| | Translocation, Genetic | 7 | 2022 | 264 | 0.410 |
Why?
| | Neoplasms | 2 | 2020 | 1250 | 0.410 |
Why?
| | Humans | 45 | 2024 | 50251 | 0.400 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2024 | 567 | 0.400 |
Why?
| | Osteolysis | 2 | 2022 | 75 | 0.390 |
Why?
| | Models, Molecular | 1 | 2013 | 342 | 0.390 |
Why?
| | Gene Expression Profiling | 9 | 2023 | 1041 | 0.370 |
Why?
| | Genome, Human | 3 | 2021 | 111 | 0.370 |
Why?
| | Chromosome Aberrations | 3 | 2023 | 297 | 0.370 |
Why?
| | Evolution, Molecular | 2 | 2021 | 99 | 0.360 |
Why?
| | Gene Expression Regulation, Neoplastic | 5 | 2024 | 828 | 0.360 |
Why?
| | Proteins | 1 | 2013 | 345 | 0.350 |
Why?
| | Prognosis | 11 | 2024 | 1959 | 0.340 |
Why?
| | Bone Marrow | 3 | 2020 | 363 | 0.320 |
Why?
| | Epigenomics | 2 | 2021 | 68 | 0.320 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2020 | 994 | 0.280 |
Why?
| | Disease Progression | 7 | 2023 | 827 | 0.250 |
Why?
| | Gene Rearrangement | 2 | 2023 | 74 | 0.250 |
Why?
| | Oncogenes | 3 | 2021 | 57 | 0.250 |
Why?
| | Chemokine CXCL12 | 1 | 2024 | 31 | 0.240 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 11 | 0.210 |
Why?
| | Burkitt Lymphoma | 1 | 2023 | 28 | 0.210 |
Why?
| | Gene Dosage | 2 | 2020 | 78 | 0.210 |
Why?
| | Epigenesis, Genetic | 3 | 2023 | 378 | 0.210 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2023 | 157 | 0.210 |
Why?
| | Signal Transduction | 3 | 2024 | 1624 | 0.210 |
Why?
| | Proto-Oncogene Proteins B-raf | 2 | 2020 | 79 | 0.200 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2024 | 316 | 0.200 |
Why?
| | Neoplasm Proteins | 2 | 2021 | 324 | 0.200 |
Why?
| | Cell Communication | 1 | 2022 | 69 | 0.200 |
Why?
| | Telomere Homeostasis | 1 | 2021 | 10 | 0.190 |
Why?
| | Ubiquitination | 1 | 2021 | 43 | 0.190 |
Why?
| | Polycomb Repressive Complex 2 | 1 | 2021 | 47 | 0.190 |
Why?
| | Chromosome Deletion | 2 | 2023 | 140 | 0.190 |
Why?
| | Loss of Heterozygosity | 2 | 2018 | 77 | 0.190 |
Why?
| | Lymphoma, B-Cell | 1 | 2021 | 63 | 0.190 |
Why?
| | Positron-Emission Tomography | 2 | 2022 | 293 | 0.180 |
Why?
| | Genes, Tumor Suppressor | 2 | 2021 | 73 | 0.180 |
Why?
| | Sequence Analysis, DNA | 2 | 2018 | 238 | 0.180 |
Why?
| | B-Lymphocytes | 1 | 2021 | 170 | 0.180 |
Why?
| | Cell Cycle | 1 | 2021 | 232 | 0.180 |
Why?
| | Cell Cycle Proteins | 1 | 2021 | 166 | 0.180 |
Why?
| | Lymphoma, Follicular | 1 | 2020 | 27 | 0.180 |
Why?
| | Exosome Multienzyme Ribonuclease Complex | 1 | 2020 | 12 | 0.180 |
Why?
| | Leukemia, Plasma Cell | 1 | 2020 | 33 | 0.170 |
Why?
| | Bone Resorption | 1 | 2022 | 302 | 0.170 |
Why?
| | Gene Regulatory Networks | 1 | 2020 | 107 | 0.170 |
Why?
| | Genes, myc | 1 | 2019 | 41 | 0.160 |
Why?
| | Mice | 7 | 2024 | 5770 | 0.160 |
Why?
| | Osteocytes | 1 | 2022 | 215 | 0.160 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2017 | 203 | 0.160 |
Why?
| | Mutagenesis | 1 | 2018 | 60 | 0.150 |
Why?
| | Transplantation, Autologous | 4 | 2024 | 470 | 0.150 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2018 | 124 | 0.150 |
Why?
| | Genome | 1 | 2018 | 65 | 0.150 |
Why?
| | Neoplasm, Residual | 1 | 2018 | 165 | 0.150 |
Why?
| | Homologous Recombination | 1 | 2018 | 41 | 0.150 |
Why?
| | Female | 11 | 2024 | 26668 | 0.150 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 2017 | 36 | 0.140 |
Why?
| | Survival Rate | 4 | 2021 | 902 | 0.140 |
Why?
| | Transcriptome | 2 | 2020 | 320 | 0.140 |
Why?
| | DNA Repair | 1 | 2018 | 193 | 0.140 |
Why?
| | Flow Cytometry | 1 | 2018 | 478 | 0.130 |
Why?
| | Cell Line, Tumor | 3 | 2024 | 1418 | 0.130 |
Why?
| | DNA Copy Number Variations | 3 | 2022 | 110 | 0.130 |
Why?
| | Aged | 8 | 2021 | 9427 | 0.130 |
Why?
| | Aged, 80 and over | 5 | 2021 | 3140 | 0.130 |
Why?
| | Remission Induction | 3 | 2021 | 207 | 0.130 |
Why?
| | Genes, Neoplasm | 1 | 2015 | 30 | 0.120 |
Why?
| | Pattern Recognition, Automated | 1 | 2015 | 42 | 0.120 |
Why?
| | Male | 11 | 2024 | 25483 | 0.120 |
Why?
| | Middle Aged | 8 | 2021 | 12234 | 0.120 |
Why?
| | Cluster Analysis | 1 | 2015 | 235 | 0.120 |
Why?
| | Follow-Up Studies | 4 | 2021 | 2180 | 0.120 |
Why?
| | Animals | 7 | 2024 | 13285 | 0.120 |
Why?
| | Databases, Protein | 1 | 2013 | 29 | 0.110 |
Why?
| | Protein Structure, Secondary | 1 | 2013 | 72 | 0.110 |
Why?
| | Sequence Alignment | 1 | 2013 | 121 | 0.110 |
Why?
| | Amino Acid Sequence | 1 | 2013 | 587 | 0.100 |
Why?
| | Chromatin | 2 | 2023 | 152 | 0.100 |
Why?
| | T-Lymphocytes | 2 | 2024 | 339 | 0.100 |
Why?
| | Adenocarcinoma | 1 | 2015 | 402 | 0.090 |
Why?
| | Breast Neoplasms | 1 | 2020 | 1184 | 0.090 |
Why?
| | Mutation Rate | 2 | 2021 | 36 | 0.090 |
Why?
| | In Situ Hybridization, Fluorescence | 2 | 2023 | 259 | 0.090 |
Why?
| | Tumor Burden | 2 | 2020 | 131 | 0.090 |
Why?
| | Alleles | 2 | 2021 | 250 | 0.090 |
Why?
| | Adult | 6 | 2021 | 13384 | 0.090 |
Why?
| | Clone Cells | 2 | 2021 | 78 | 0.090 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 2 | 2021 | 66 | 0.080 |
Why?
| | Lung Neoplasms | 1 | 2015 | 609 | 0.080 |
Why?
| | DNA, Neoplasm | 2 | 2020 | 147 | 0.080 |
Why?
| | Histones | 2 | 2021 | 313 | 0.080 |
Why?
| | DNA Mutational Analysis | 2 | 2020 | 176 | 0.080 |
Why?
| | Treatment Outcome | 4 | 2020 | 5186 | 0.080 |
Why?
| | DNA Methylation | 2 | 2023 | 550 | 0.070 |
Why?
| | Recurrence | 2 | 2021 | 661 | 0.070 |
Why?
| | Genomic Instability | 2 | 2018 | 93 | 0.070 |
Why?
| | Risk Factors | 3 | 2021 | 3608 | 0.070 |
Why?
| | Cell Proliferation | 2 | 2021 | 1015 | 0.060 |
Why?
| | Internet | 2 | 2018 | 258 | 0.060 |
Why?
| | Ferritins | 1 | 2024 | 30 | 0.060 |
Why?
| | Killer Cells, Natural | 1 | 2024 | 108 | 0.060 |
Why?
| | Myeloid Progenitor Cells | 1 | 2023 | 18 | 0.060 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2024 | 127 | 0.060 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2024 | 213 | 0.060 |
Why?
| | Antibodies | 1 | 2024 | 155 | 0.060 |
Why?
| | Proteasome Inhibitors | 1 | 2024 | 104 | 0.050 |
Why?
| | Integrin beta Chains | 1 | 2023 | 14 | 0.050 |
Why?
| | Integrins | 1 | 2023 | 31 | 0.050 |
Why?
| | Oxidative Phosphorylation | 1 | 2023 | 40 | 0.050 |
Why?
| | B-Cell Maturation Antigen | 1 | 2024 | 91 | 0.050 |
Why?
| | Cytogenetic Analysis | 1 | 2023 | 82 | 0.050 |
Why?
| | TNF Receptor-Associated Factor 3 | 1 | 2022 | 13 | 0.050 |
Why?
| | Cystatin M | 1 | 2022 | 20 | 0.050 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 2023 | 93 | 0.050 |
Why?
| | Immunoglobulins | 1 | 2023 | 80 | 0.050 |
Why?
| | Forkhead Transcription Factors | 1 | 2023 | 112 | 0.050 |
Why?
| | Phylogeny | 1 | 2022 | 234 | 0.050 |
Why?
| | Syndecan-1 | 1 | 2021 | 72 | 0.050 |
Why?
| | Spliceosomes | 1 | 2021 | 10 | 0.050 |
Why?
| | RANK Ligand | 1 | 2022 | 179 | 0.050 |
Why?
| | Transcriptional Activation | 1 | 2021 | 121 | 0.050 |
Why?
| | RNA Splicing | 1 | 2021 | 37 | 0.050 |
Why?
| | Alternative Splicing | 1 | 2021 | 56 | 0.050 |
Why?
| | Cyclin D2 | 1 | 2020 | 20 | 0.050 |
Why?
| | Aneuploidy | 1 | 2020 | 16 | 0.050 |
Why?
| | Spatio-Temporal Analysis | 1 | 2020 | 10 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-maf | 1 | 2020 | 19 | 0.050 |
Why?
| | Chromosomes, Human, Pair 4 | 1 | 2020 | 31 | 0.050 |
Why?
| | Gene Expression Regulation, Leukemic | 1 | 2020 | 33 | 0.040 |
Why?
| | Chromosomes, Human, Pair 11 | 1 | 2020 | 54 | 0.040 |
Why?
| | Histone Code | 1 | 2020 | 32 | 0.040 |
Why?
| | Cyclin D1 | 1 | 2020 | 56 | 0.040 |
Why?
| | ras Proteins | 1 | 2020 | 64 | 0.040 |
Why?
| | Ecosystem | 1 | 2021 | 64 | 0.040 |
Why?
| | Phosphoproteins | 1 | 2021 | 108 | 0.040 |
Why?
| | Chromosomes, Human, Pair 14 | 1 | 2020 | 75 | 0.040 |
Why?
| | Single-Cell Analysis | 1 | 2020 | 62 | 0.040 |
Why?
| | Mice, Transgenic | 1 | 2021 | 551 | 0.040 |
Why?
| | Cell Differentiation | 1 | 2022 | 652 | 0.040 |
Why?
| | Protein Disulfide-Isomerases | 1 | 2019 | 14 | 0.040 |
Why?
| | Genes, Immunoglobulin Heavy Chain | 1 | 2019 | 13 | 0.040 |
Why?
| | DNA | 1 | 2023 | 542 | 0.040 |
Why?
| | Genetic Variation | 1 | 2020 | 215 | 0.040 |
Why?
| | Melphalan | 1 | 2020 | 174 | 0.040 |
Why?
| | Neoplasm Invasiveness | 1 | 2020 | 268 | 0.040 |
Why?
| | Multivariate Analysis | 1 | 2021 | 578 | 0.040 |
Why?
| | Osteoclasts | 1 | 2022 | 428 | 0.040 |
Why?
| | Osteogenesis | 1 | 2022 | 354 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2021 | 641 | 0.040 |
Why?
| | Maintenance Chemotherapy | 1 | 2019 | 49 | 0.040 |
Why?
| | Disease Models, Animal | 1 | 2024 | 1470 | 0.040 |
Why?
| | Apoptosis | 1 | 2024 | 1115 | 0.040 |
Why?
| | Cell Survival | 1 | 2020 | 602 | 0.040 |
Why?
| | Promoter Regions, Genetic | 1 | 2020 | 475 | 0.040 |
Why?
| | 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2017 | 8 | 0.040 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2017 | 27 | 0.040 |
Why?
| | Genome-Wide Association Study | 1 | 2018 | 166 | 0.040 |
Why?
| | Information Dissemination | 1 | 2018 | 79 | 0.040 |
Why?
| | Reproducibility of Results | 1 | 2021 | 1189 | 0.040 |
Why?
| | STAT3 Transcription Factor | 1 | 2017 | 81 | 0.040 |
Why?
| | Fibroblast Growth Factors | 1 | 2017 | 47 | 0.040 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2017 | 155 | 0.040 |
Why?
| | Prospective Studies | 1 | 2023 | 2379 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2020 | 1377 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2018 | 407 | 0.030 |
Why?
| | Genes, ras | 1 | 2016 | 43 | 0.030 |
Why?
| | Thalidomide | 1 | 2019 | 377 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2018 | 465 | 0.030 |
Why?
| | Genes, p53 | 1 | 2016 | 51 | 0.030 |
Why?
| | Cohort Studies | 1 | 2020 | 1397 | 0.030 |
Why?
| | Models, Genetic | 1 | 2016 | 170 | 0.030 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2016 | 140 | 0.030 |
Why?
| | Antineoplastic Agents | 1 | 2024 | 1186 | 0.030 |
Why?
| | Survival Analysis | 1 | 2017 | 666 | 0.030 |
Why?
| | Stem Cell Transplantation | 1 | 2016 | 181 | 0.030 |
Why?
| | Dogs | 1 | 2015 | 185 | 0.030 |
Why?
| | Databases, Genetic | 1 | 2015 | 88 | 0.030 |
Why?
| | Time Factors | 1 | 2021 | 2911 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2015 | 91 | 0.030 |
Why?
| | Genetic Testing | 1 | 2015 | 118 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2016 | 687 | 0.030 |
Why?
| | Retrospective Studies | 1 | 2024 | 6172 | 0.020 |
Why?
| | Child | 1 | 2023 | 6854 | 0.020 |
Why?
|
|
Ashby's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|